1-6 of 6
Edward Dow
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients (pts) with Acute Leukemia with and without Mixed-Lineage Leukemia ( MLL )-Rearrangement or Nucleophosmin 1 ( NPM1 ) Mutation

Naval Daver, John Affinito, Hongliang Cai, Hanna Dobrowolska, Edward Dow, Ken Eguchi, Gregory Song, Jay Stoudemire, Akinobu Watanbe, Philip Komarnitsky
Journal: Blood
Blood (2021) 138 (Supplement 1): 4431.
https://doi.org/10.1182/blood-2021-147856
Published: 2021
Journal Articles

Comparative Effectiveness Research on the Treatment Outcomes of Subcutaneous (SC) and Intravenous (IV) Bortezomib (BTZ) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)

Robert M. Rifkin, Esprit Ma, MPH, Robyn Harrell, MS, Yanyan Zhu, PhD MPH, Edward Dow, MD, Liviu Niculescu, MDPhD, Vijayveer Bonthapally, PhD
Journal: Blood
Blood (2015) 126 (23): 4506.
https://doi.org/10.1182/blood.V126.23.4506.4506
Published: 2015
Journal Articles

Subcutaneous (SQ) Bortezomib (BTZ) in Patients (Pts) with Relapsed Mantle Cell Lymphoma (MCL): Retrospective, Observational Study of Treatment Patterns and Outcomes in US Community Oncology Practices

Alan P Skarbnik, MD, Esprit Ma, MPH, Marie-Hélène Lafeuille, MA, Jonathan Fortier, MA, Tatyana Feldman, MD, Mei Sheng Duh, MPH, ScD, Yvette Ng, MS, MBA, Helgi van de Velde, MD PhD, Edward Dow, MD, Liviu Niculescu, MD, Vijayveer Bonthapally, PhD, Andre Goy, MD MS
Journal: Blood
Blood (2014) 124 (21): 1740.
https://doi.org/10.1182/blood.V124.21.1740.1740
Published: 2014
Journal Articles

Impact Of Route Of Bortezomib (B) Administration On Dose Intensity and Time To Dose Reduction In Previously Untreated Patients (Pts) With Multiple Myeloma (MM)

Robert M Rifkin, MD, FACP, Clara Chen, MS, Rahul Dhanda, Ph.D, Debra Rembert, RN, MSN, NP, Abbie Ba-Mancini, BS MBA, Esprit Ma, MPH, Yanyan Zhu, Ph.D, MPH, Edward Dow, MD, Liviu Niculescu, MD
Journal: Blood
Blood (2013) 122 (21): 1941.
https://doi.org/10.1182/blood.V122.21.1941.1941
Published: 2013
Journal Articles

Higher Cumulative Bortezomib Dose Results In Better Overall Survival (OS) In Patients With Previously Untreated Multiple Myeloma (MM) Receiving Bortezomib-Melphalan-Prednisone (VMP) In The Phase 3 VISTA Study

Maria-Victoria Mateos, MD, Ph.D, Paul G. Richardson, MD, Hongliang Shi, Ph.D, Liviu Niculescu, MD, Jennifer Elliott, Ph.D, Edward Dow, MD, Helgi van de Velde, Jesús F San Miguel, MD
Journal: Blood
Blood (2013) 122 (21): 1968.
https://doi.org/10.1182/blood.V122.21.1968.1968
Published: 2013
Journal Articles

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

Jacob P. Laubach, MD, Jesús F San Miguel, MD, Pieter Sonneveld, MD, Ph.D, Robert Z. Orlowski, M.D., Ph.D., Philippe Moreau, MD, Laura Rosiñol, MD, Javid J Moslehi, MD, Edward A Faber, Jr., DO, MS, Peter M Voorhees, Loreta Marquez, MD, Avinash Desai, MD, Helgi van de Velde, Jennifer Elliott, Ph.D, Hongliang Shi, Ph.D, Edward Dow, MD, Nishith Jobanputra, DO, Dixie-Lee Esseltine, MD, FRCPC, Liviu Niculescu, MD, Kenneth C. Anderson, MD, Sagar Lonial, M.D., Paul G. Richardson, MD
Journal: Blood
Blood (2013) 122 (21): 3187.
https://doi.org/10.1182/blood.V122.21.3187.3187
Published: 2013